ArticleAlimentary pharmacology & therapeutics2020
Liver involvement is not associated with mortality: results from a large cohort of SARS-CoV-2-positive patients.
Article in Alimentary pharmacology & therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Prognostic factors for mortality, intensive care unit and hospital admission due to SARS-CoV-2: a systematic review and meta-analysis of cohort studies in Europe.European respiratory review : an official journal of the European Respiratory Society · 2022Pooled it
- Early changes in laboratory parameters are predictors of mortality and ICU admission in patients with COVID-19: a systematic review and meta-analysis.Medical microbiology and immunology · 2021Pooled it
- Hemostatic System (Fibrinogen Level, D-Dimer, and FDP) in Severe and Non-Severe Patients With COVID-19: A Systematic Review and Meta-Analysis.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisPooled it
- Gastrointestinal Symptoms and Abnormal Liver Biochemistry in Patients with COVID-19 Pneumonia Admitted to the Department of Gastroenterology After Ending Zero-COVID Policy in China.Advances in therapy · 2026Article
- Outcomes of SARS-CoV-2 infection in patients under treatment with pharmacological immunosuppression. A Swiss cohort study.Archives of medical science : AMS · 2025Article
- Liver dysfunction in adults with COVID-19 infection: A longitudinal study with transient elastography evaluation.JGH open : an open access journal of gastroenterology and hepatology · 2024Article
- Liver damage profile in COVID-19 pregnant patients.Cell communication and signaling : CCS · 2024Article
- Effects of COVID-19 on the Liver and Mortality in Patients with SARS-CoV-2 Pneumonia Caused by Delta and Non-Delta Variants: An Analysis in a Single Centre.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Microvascular Thrombosis and Liver Fibrosis Progression: Mechanisms and Clinical Applications.Cells · 2023Review
- Liver Damage and COVID-19: At Least a "Two-Hit" Story in Systematic Review.Current issues in molecular biology · 2023Review
- COVID-19 and the liver: Are footprints still there?World journal of gastroenterology · 2023Review
- SARS-CoV-2 Establishes a Productive Infection in Hepatoma and Glioblastoma Multiforme Cell Lines.Cancers · 2023Article
- Liver injury in COVID-19: Clinical features, potential mechanisms, risk factors and clinical treatments.World journal of gastroenterology · 2023Review
- COVID-19-induced liver injury in adult patients: A brief overview.World journal of virology · 2022Review
- Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper.Journal of hepatology · 2022Article
- COVID-19-associated liver injury: Clinical characteristics, pathophysiological mechanisms and treatment management.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Review
- Liver damage in the context of SARS-CoV-2. Covid-19 treatment and its effects on the liver.Journal of medicine and life · 2022Review
- Liver function tests in COVID 19: A retrospective record-based study from a tertiary care centre in urban Maharashtra, India.Medical journal, Armed Forces India · 2022Article
- COVID-19 and liver diseases, what we know so far.World journal of clinical cases · 2022Review
- Hepatocellular liver injury in hospitalized patients affected by COVID-19: Presence of different risk factors at different time points.Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2022Observational
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is frequently associated with liver test abnormalities.
aimsTo describe the evolution of liver involvement during SARS-CoV-2 infection and its effect on clinical course and mortality.
methodsData of 515 SARS-CoV-2-positive patients were collected at baseline and during follow-up, last evaluation or death. Stratification based on need for hospitalisation, severe disease and admission to intensive care unit (ICU) was performed. The association between liver test abnormalities (baseline and peak values) and ICU admission or death was also explored.
resultsLiver test abnormalities were found in 161 (31.3%) patients. Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and gamma glutamyl transferase (GGT) were increased in 20.4%, 19% and 13.6% of patients, respectively. Baseline liver test abnormalities were associated with increased risk of ICU admission (OR 2.19 [95% CI 1.24-3.89], P = 0.007) but not with mortality (OR 0.84 [95% CI 0.49-1.41], P = 0.51). Alkaline phosphatase (ALP) peak values were correlated with risk of death (OR 1.007 [95% CI 1.002-1.01], P = 0.005) along with age, multiple comorbidities, acute respiratory distress syndrome, ICU admission and C-reactive protein. Alterations of liver tests worsened within 15 days of hospitalisation; however, in patients with the longest median follow-up, the prevalence of liver test alterations decreased over time, returning to around baseline levels.
conclusionsIn SARS-CoV-2-positive patients without pre-existing severe chronic liver disease, baseline liver test abnormalities are associated with the risk of ICU admission and tend to normalise over time. The ALP peak value may be predictive of a worse prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.